You are here

  • Home
  • Archive
  • Volume 9, Issue 11
  • Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

Article metrics

Article menu

See original article:

Download PDFPDF

Correction
Correction: KEYNOTE-022 part 3: a randomized, double-blind, phase 2 study of pembrolizumab, dabrafenib, and trametinib in BRAF-mutant melanoma

 

Online download statistics by month:

Online download statistics by month: November 2021 to April 2026

AbstractFullPdf
Nov 2021019348
Dec 2021013221
Jan 202208617
Feb 202205818
Mar 202203918
Apr 202203812
May 202207617
Jun 202209718
Jul 20220272
Aug 20220465
Sep 202202813
Oct 202204422
Nov 202201812
Dec 20220144
Jan 20230144
Feb 20230362
Mar 20230197
Apr 202301712
May 202301413
Jun 2023095
Jul 202301310
Aug 2023097
Sep 20230177
Oct 20230249
Nov 20230229
Dec 20230375
Jan 20240203
Feb 20240203
Mar 202402326
Apr 202402112
May 2024084
Jun 20240176
Jul 20240335
Aug 20240199
Sep 202401910
Oct 20240198
Nov 20240168
Dec 20240173
Jan 20250159
Feb 20250114
Mar 20250152
Apr 20250374
May 20250114
Jun 20250154
Dec 2025010
Jan 2026010
Apr 2026010
Total01466441